These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19640960)

  • 21. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
    RISE Consortium
    Diabetes Care; 2014; 37(3):780-8. PubMed ID: 24194506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
    Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
    Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
    ; Crandall J; Schade D; Ma Y; Fujimoto WY; Barrett-Connor E; Fowler S; Dagogo-Jack S; Andres R
    J Gerontol A Biol Sci Med Sci; 2006 Oct; 61(10):1075-81. PubMed ID: 17077202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
    Armato JP; DeFronzo RA; Abdul-Ghani M; Ruby RJ
    Lancet Diabetes Endocrinol; 2018 Oct; 6(10):781-789. PubMed ID: 30224284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
    Knowler WC; Barrett-Connor E; Fowler SE; Hamman RF; Lachin JM; Walker EA; Nathan DM;
    N Engl J Med; 2002 Feb; 346(6):393-403. PubMed ID: 11832527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1).
    Snehalatha C; Mary S; Selvam S; Sathish Kumar CK; Shetty SB; Nanditha A; Ramachandran A
    Diabetes Care; 2009 Oct; 32(10):1796-801. PubMed ID: 19587369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
    Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2019 Apr; 42(4):601-608. PubMed ID: 30877090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of type II diabetes mellitus in population of Krakow].
    Szurkowska M; Szybiński Z; Nazim A; Szafraniec K; Jedrychowski W
    Pol Arch Med Wewn; 2001 Sep; 106(3):771-9. PubMed ID: 11928585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
    The Diabetes Prevention Program Research Group
    Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
    Aroda VR; Knowler WC; Crandall JP; Perreault L; Edelstein SL; Jeffries SL; Molitch ME; Pi-Sunyer X; Darwin C; Heckman-Stoddard BM; Temprosa M; Kahn SE; Nathan DM;
    Diabetologia; 2017 Sep; 60(9):1601-1611. PubMed ID: 28770322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
    Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.
    Sylvetsky AC; Chandran A; Talegawkar SA; Welsh JA; Drews K; El Ghormli L
    J Acad Nutr Diet; 2020 Aug; 120(8):1348-1358.e6. PubMed ID: 32711855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
    Wittert G; Bracken K; Robledo KP; Grossmann M; Yeap BB; Handelsman DJ; Stuckey B; Conway A; Inder W; McLachlan R; Allan C; Jesudason D; Fui MNT; Hague W; Jenkins A; Daniel M; Gebski V; Keech A
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):32-45. PubMed ID: 33338415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.